C12Y 204/02004
Thymidine phosphorylase
Official title: Thymidine phosphorylase (2.4.2.4)
C12Y204/02004 (Thymidine phosphorylase) appears on 12 US grants and 26 published applications in this corpus.
Search patents in C12Y- Granted patents
- 12
- Published applications
- 26
- Assignees
- 6
- Inventors
- 20
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 8 |
| 2019 | 5 | 8 |
| 2020 | 1 | 2 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy4 Aug 2026US 12,698,482 B2Entrada Therapeutics, Inc.
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes23 Sep 2025US 12,419,970 B2The Trustees of Columbia University in the City of New York
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy21 May 2024US 11,987,821 B2Entrada Therapeutics, Inc.
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy9 Nov 2021US 11,168,310 B2Entrada Therapeutics, Inc.
- Erythroid cells comprising phenylalanine ammonia lyase11 Feb 2020US 10,557,119 B2Rubius Therapeutics, Inc.
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy10 Apr 2025US 2025/0115885 A1Entrada Therapeutics, Inc.
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy3 Feb 2022US 2022/0033787 A1Entrada Therapeutics, Inc.
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes8 Apr 2021US 2021/0100917 A1The Trustees of Columbia University in the City of New York
- Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy12 Nov 2020US 2020/0354697 A1Entrada Therapeutics, Inc.
- Erythroid cells comprising phenylalanine hydroxylase2 Jan 2020US 2020/0002674 A1Rubius Therapeutics, Inc.
Most cited
By later US patents
- Synthetic membrane-receiver complexes35US 9,644,180 B2Rubius Therapeutics, Inc. · 2017
- Synthetic membrane-receiver complexes18US 10,329,531 B2Rubius Therapeutics, Inc. · 2019
- Synthetic membrane-receiver complexes15US 10,253,296 B2Rubius Therapeutics, Inc. · 2019
- Synthetic membrane-receiver complexes13US 10,344,263 B2Rubius Therapeutics, Inc. · 2019
- Synthetic membrane-receiver complexes10US 10,301,594 B1Rubius Therapeutics, Inc. · 2019